← All Adial Pharmaceuticals, INC filings

Adial Pharmaceuticals, INC S-1 registration statements

Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.

NASDAQ
ADIL
Adial Pharmaceuticals, INC
S-1/A: Adial Pharmaceuticals Seeks Up to $4.3 Million in Public Offering Amidst Severe Financial Distress and Nasdaq Delisting Threats
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, is conducting a 'best efforts' public offering of common stock and warrants to raise up to $4.325 million, while facing substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing non-compliance.
NASDAQ
ADIL
Adial Pharmaceuticals, INC
S-1: Adial Pharmaceuticals Launches Public Offering Amidst Going Concern Doubts and Nasdaq Listing Challenges
Adial Pharmaceuticals, a clinical-stage biopharmaceutical company, is offering up to 7.59 million shares of common stock and associated warrants to raise approximately $4.325 million, as it faces significant accumulated deficits, recurring losses, and ongoing Nasdaq listing compliance issues.
NASDAQ
ADIL
Adial Pharmaceuticals, INC
S-1: Adial Pharmaceuticals Files for $5 Million Common Stock Resale by Alumni Capital
Adial Pharmaceuticals has filed a registration statement for the resale of up to 5,000,000 shares of its common stock by Alumni Capital LP.